open access

Vol 14, No 2 (2018)
Review paper
Published online: 2018-04-26
Get Citation

Management of patients with metastatic castration-resistant prostate cancer — first-line treatment options according to the Polish National Health Found therapeutic program

Wojciech Rogowski, Adriana Zielska, Jakub Żołnierek
DOI: 10.5603/OCP.2018.0014
·
Oncol Clin Pract 2018;14(2):96-99.

open access

Vol 14, No 2 (2018)
REVIEW ARTICLES
Published online: 2018-04-26

Abstract

Prostate cancer is one of the most common malignancies among men worldwide. According to ESMO recommendations, systemic treatment of castrate-resistant prostate cancer (CRPC) patients includes hormonal treatment, radionuclides, and immunotherapy, and the choice of appropriate method depends, among others, on clinical symptoms of disease and possible presence of distant metastases. Polish recommendations regarding systemic treatment of CRPC are different, mainly due to the distinct reimbursement conditions for individual drugs. The purpose of the subsequent two publications is to present the options of systemic treatment for CRPC patients within the Polish National Health Fund drug program. The first of the articles presents first-line treatment.

Abstract

Prostate cancer is one of the most common malignancies among men worldwide. According to ESMO recommendations, systemic treatment of castrate-resistant prostate cancer (CRPC) patients includes hormonal treatment, radionuclides, and immunotherapy, and the choice of appropriate method depends, among others, on clinical symptoms of disease and possible presence of distant metastases. Polish recommendations regarding systemic treatment of CRPC are different, mainly due to the distinct reimbursement conditions for individual drugs. The purpose of the subsequent two publications is to present the options of systemic treatment for CRPC patients within the Polish National Health Fund drug program. The first of the articles presents first-line treatment.

Get Citation

Keywords

prostate cancer, castration-resistant prostate cancer, systemic treatment, first-line setting

About this article
Title

Management of patients with metastatic castration-resistant prostate cancer — first-line treatment options according to the Polish National Health Found therapeutic program

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 2 (2018)

Article type

Review paper

Pages

96-99

Published online

2018-04-26

DOI

10.5603/OCP.2018.0014

Bibliographic record

Oncol Clin Pract 2018;14(2):96-99.

Keywords

prostate cancer
castration-resistant prostate cancer
systemic treatment
first-line setting

Authors

Wojciech Rogowski
Adriana Zielska
Jakub Żołnierek

References (15)
  1. P J. Wysocki, T. Borkowski, Nowotwory układu moczowo-płciowego. W: Onkologia kliniczna. Red. M. Krzakowski, P. Potemski, K. Warzocha, P. Wysocki. Via Medica, Gdańsk 2015.
  2. Krajowy rejestr nowotworów. http://onkologia.org.pl/ (ostatni dostęp 27.12. 2017 roku).
  3. J. Didkowska, Epidemiologia nowotworów układu moczowo-płciowego w Polsce. W: Nowotwory układu moczowo-połciowego. Red. E. Senkus-Konefka, R. Zdrojowy. Via Medica, Gdańsk .
  4. Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26(suppl 5): v69–v77.
  5. P. Wysocki, Miejsce octanu abirateronu w leczeniu chorych na przerzutowego raka gruczołu krokowego. Onkologia w praktyce klinicznej – edukacja. 2017; 3: 247–251.
  6. A. Borówka, J. Fijuth, P. Potemski, Rak gruczołu krokowego. W: Zalecenia postepowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Red. M. Krzakowski, K. Warzocha. Via Medica, Gdańsk 2013.
  7. E. Senkus-Konefka, Leczenie systemowe raka gruczołu krokowego. W: Nowotwory układu moczowo-połciowego. Red. E. Senkus-Konefka, R. Zdrojowy. Via Medica, Gdańsk 2013.
  8. B. Itrych, Rak gruczołu krokowego oporny na kastrację – obecne możliwości leczenia w ramach programu lekowego NFZ. Onkologia po dyplomie z hematologią. 2017; 14: 36–43.
  9. B. Itrych, Terapia hormonalna chorych na raka gruczołu krokowego – deprywacja androgenowa. Onkologia po dyplomie z hematologią. 2017; 2: 23–26.
  10. T. Gołąbek, P. L. Chłosta. Podsumowanie opartych na dowodach zaleceń panelu ekspertów dotyczących deprywacji androgenowej w leczeniu miejscowego i zaawansowanego raka gruczołu krokowego. Przegląd Urologiczny. 2016; 99: 30–33.
  11. ZYTIGATM Charakterystyka Produktu Leczniczego, 2017 (https://ec. europa eu/health/documents/community-register/2016/20161109136263/anx_136263_pl pdf).
  12. Załącznik B. 56. LECZENIE OPORNEGO NA KASTRACJĘ RAKA GRUCZOŁU KROKOWEGO (ICD-10 C61) (http://www.mz.gov.pl/leki/refundacja/programy-lekowe/).
  13. Fizazi K, Flaig TW, Ohlmann CH, et al. Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials. Proc Am Soc Clin Oncol. 2014; 32(suppl 4): abstract 20.
  14. Beer T, Armstrong A, Rathkopf D, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine. 2014; 371(5): 424–433.
  15. Parker C, Nilsson S, Heinrich D, et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213–223.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl